Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

作者：Nathalie A. Johnson, Pier Luigi Zinzani, Eva Domingo‐Doménech, Joshua Brody, Justin Kline, Bijal Shah, Amitkumar Mehta, Hervé Ghesquières, Kerry J. Savage, Paul M. Barr, Armando Santoro, Silvia Ferrari, David Cunningham, Graham P. Collins, Michelle A. Fanale, Jennifer Krajewski, Alev Akyol, Russell Crowe, Rachael Wen, John Kuruvilla · 发表于：Future Oncology · 年份：2025 · DOI：10.1080/14796694.2025.2599082 · 被引用次数：1 · 研究领域：Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research、CAR-T cell therapy research

AIMS: Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed or refractory (R/R) disease after first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, and outcomes are poor after hematopoietic stem cell transplantation failure. CheckMate 436 (NCT02581631) was a phase 1/2 study to evaluate the efficacy and safety of nivolumab, a PD-1/PD-L1 inhibitor, plus brentuximab vedotin (BV) for the treatment of R/R non-Hodgkin lymphoma. MATERIALS AND METHODS: Adult patients received nivolumab plus BV in 3-week cycles. The primary endpoint was overall response rate (ORR). Here, we report the results from the R/R DLBCL cohort (n = 42). RESULTS: With a median follow-up of 7.7 months, the ORR was 28.6% (n = 12), and 7.1% (n = 3) of patients achieved a complete response. Median duration of response (95% CI) was 3.6 (1.2-36.5) months. All patients experienced an adverse event (AE), most commonly diarrhea (n = 20, 47.6%). Grade 3/4 and 5 AEs occurred in 24 (57.1%) and 4 (9.5%) patients, respectively. Any-grade treatment-related AEs occurred in 35 (83.3%) patients. No new safety signals were identified. CONCLUSIONS: Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.